Receive a FREE Mesothelioma Treatment
Information Packet

Mesothelioma

Decitabine/Depsipeptide Infusion in Patients with Pulmonary and Pleural Malignancies

Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion in Patients with Pulmonary and Pleural Malignancies

Background:
Preliminary research indicates that the drug decitabine (DAC) enhances the immune response to tumors and may enable the p16 gene, called the 'suppressor gene,' to function normally. The drug depsipeptide (DP) appears to help kill cancer cells and prevent the growth of new cancer cells. These two drugs have been administered separately in the past. This study will examine the effect of the two drugs when they are given together

Location and Contact Information:
Maryland
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, 20892, United States;
Recruiting
Tricia Kunst, R.N. 3014024399 kunstt@mail.nih.gov